Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,501–1,600 of 15,747
Covid-19 Vaccine Protection among Children and Adolescents in Qatar
Chemaitelly, H. S., AlMukdad, S., Ayoub, H. H., Altarawneh, H. N., Coyle, P. V., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210058 · Cited by 77
Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2
Petter, E., Mor, O., Zuckerman, N., Oz-Levi, D., Younger, A., Aran, D., & Erlich, Y. (2021) · doi:10.1101/2021.02.08.21251329 · Cited by 71
Samanovic-Golden, M., Cornelius, A., Wilson, J. P., Karmacharya, T., Gray-Gaillard, S., Allen, J., Hyman, S., Moritz, G., Ali, M., Koralov, S. B., et al. (2021) · medRxiv · doi:10.1101/2021.02.07.21251311 · Cited by 69
Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J. E., Perl, Y., & Weng, C. (2022) · JMIR Public Health and Surveillance · doi:10.2196/35311 · Cited by 70
Mesa, D. O., Hogan, A. B., Watson, O. J., Charles, G. D., Hauck, K., Ghani, A. C., & Winskill, P. (2022) · Communications Medicine · doi:10.1038/s43856-022-00075-x · Cited by 73
“Protection due to vaccination is modelled at two stages in the model; (1) reducing the probability of infection upon exposure (efficacy against infection) and (2) reducing the probability of hospitalisation being indicated after developing disease (efficacy against hospitalisation and death).”
BackgroundmRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 94
“[86] Polack FP , Thomas SJ , Kitchin N , Absalon J , Gurtman A , Lockhart S , et al.”
BackgroundVaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination
Fertig, T. E., Chiţoiu, L., Marta, D. S., Ionescu, V., Cismasiu, V. B., Radu, E., Angheluta, G., Dobre, M., Serbanescu, A., Hinescu, M. E., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071538 · Cited by 73
“Briefly, the two licensed COVID-19 mRNA vaccines contain synthetic mRNA that codes the proline-stabilised prefusion conformation of the SARS-CoV-2 spike glycoprotein (S-protein) [3,4].”
BackgroundNose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties
Kurano, T., Kanazawa, T., Ooba, A., Masuyama, Y., Maruhana, N., Yamada, M., Iioka, S., Ibaraki, H., Kosuge, Y., Kondo, H., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.017 · Cited by 80
Brufau, S. R., Chopra, A., Ryu, A. J., Gel, E. S., Raskar, R., Kremers, W. K., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1087 · Cited by 87
Kim, S., Wi, Y. M., Yun, S. Y., Ryu, J. S., Shin, J. M., Lee, E. H., Seo, K. H., Lee, S. H., & Peck, K. R. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e107 · Cited by 77
Haabeth, O. A. W., Lohmeyer, J. J. K., Sallets, A., Blake, T. R., Sagiv-Barfi, I., Czerwinski, D. K., McCarthy, B., Powell, A. E., Wender, P. A., Waymouth, R. M., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00361 · Cited by 77
Nucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 91
Suzuki, Y., & Gychka, S. G. (2021) · Vaccines · doi:10.3390/vaccines9010036 · Cited by 75
Lumley, S. F., Rodger, G., Constantinides, B., Sanderson, N., Chau, K. K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab608 · Cited by 70
Self-citationRecent Advances and Prospects in RNA Drug Development
Tani, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212284 · Cited by 81
Coggins, S. A., Laing, E. D., Olsen, C. H., Goguet, E., Moser, M. S., Jackson-Thompson, B. M., Samuels, E. C., Pollett, S. D., Tribble, D. R., Davies, J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab575 · Cited by 79
COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern
Zeyaullah, M., AlShahrani, A. M., Muzammil, K., Ahmad, I., Alam, S., Khan, W. H., & Ahmad, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.693916 · Cited by 77
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
He, Z., Le, Z., Shi, Y., Liu, L., Liu, Z., & Chen, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310401 · Cited by 75
Arashiro, T., Arima, Y., Muraoka, H., Sato, A., Oba, K., Uehara, Y., Arioka, H., Yanai, H., Kuramochi, J., Ihara, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac635 · Cited by 70
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 74
Determinan Kesediaan Masyarakat menerima Vaksinasi Covid-19 di Sulawesi Tengah
Ichsan, D. S., Hafid, F., Ramadhan, K., & Taqwin, T. (2021) · Poltekita Jurnal Ilmu Kesehatan · doi:10.33860/jik.v15i1.430 · Cited by 116
Canas, L. S., Molteni, E., Deng, J., Sudre, C. H., Murray, B. A. K., Kerfoot, E., Antonelli, M., 陳立遠, Rjoob, K., Pujol, J. C., et al. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00056-0 · Cited by 106
Faustman, D. L., Lee, A. J., Hostetter, E. R., Aristarkhova, A., Ng, N., Shpilsky, G. F., Tran, L., Wolfe, G. E., Takahashi, H., Dias, H. F., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100728 · Cited by 80
Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
Clemente, B., Denis, M., Silveira, C. P., Schiavetti, F., Brazzoli, M., & Stranges, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294929 · Cited by 76
Adigwe, O. P. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100112 · Cited by 78
“However, though the present cohort of COVID-19 vaccines were developed expeditiously, there is little or no evidence that suggests that safety had been sacrificed for speed [22].”
Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review
Boroumand, A. B., Forouhi, M., Karimi, F., Moghadam, A. S., Naeini, L. G., Kokabian, P., & Naderi, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940357 · Cited by 76
Bartels, L. E., Ammitzbøll, C. G., Andersen, J. B., Vils, S. R., Mistegaard, C. E., Johannsen, A. D., Hermansen, M. F., Thomsen, M. K., Erikstrup, C., Hauge, E., et al. (2021) · Rheumatology International · doi:10.1007/s00296-021-04972-7 · Cited by 70
Roadmap to 2030 for Drug Evaluation in Older Adults
Liu, Q., Schwartz, J. B., Slattum, P. W., Lau, S. W. J., Guinn, D., Madabushi, R., Burckart, G. J., Califf, R. M., Cerreta, F., Cho, C., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2452 · Cited by 78
SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn
Connors, M., Graham, B. S., Lane, H. C., & Fauci, A. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0111 · Cited by 75
Nanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery
Hatit, M. Z. C., Dobrowolski, C. N., Lokugamage, M. P., Loughrey, D., Ni, H., Zurla, C., Sanchez, A. J. D. S., Radmand, A., Huayamares, S. G., Zenhausern, R., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01138-9 · Cited by 76
Bauer, S., Contreras, S., Dehning, J., Linden, M., Iftekhar, E. N., Mohr, S., Olivera‐Nappa, Á., & Priesemann, V. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009288 · Cited by 81
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
Clarke, C., Prendecki, M. F., Dhutia, A., Gan, J. J. L., Edwards, C., Prout, V., Lightstone, L., Parker, E. L., Marchesin, F., Griffith, M. E., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.009 · Cited by 73
Chen, Y., Cheng, L., Lian, R., Song, Z., & Tian, J. (2021) · BioScience Trends · doi:10.5582/bst.2021.01061 · Cited by 76
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
Lee, E., Moreira, M. B., Al-Samkari, H. T., Cuker, A. C., DiRaimo, J. M. , Gernsheimer, T., Kruse, A., Kessler, C. M., Kruse, C., Leavitt, A. D., et al. (2021) · Blood · doi:10.1182/blood.2021013411 · Cited by 69
mRNA therapeutics: New vaccination and beyond
Wei, H. Y., Zheng, L., & Wang, Z. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.02.022 · Cited by 81
“pplication of mRNA vaccines by BioNTech/Pfizer [57] and Moderna 58] against SARS-CoV-2.”
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F. M., Chadwick, D., Clark, R., Cosgrove, C. A., Galloway, J. B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac803 · Cited by 73
“Similar differences in responses related to age and prior exposure have been described for other COVID-19 vaccines and are consistent with immunosenescence and priming, respectively [20, 21].”
Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 77
Chung, D. J., Shah, G. L., Devlin, S. M., Ramanathan, L. V., Doddi, S., Pessin, M. S., Hoover, E., Marcello, L. T., Young, J. C., Boutemine, S. R., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0139 · Cited by 68
Corbeddu, M., Diociaiuti, A., Vinci, M. R., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17268 · Cited by 69
Shacham, M., Greenblatt‐Kimron, L., Hamama‐Raz, Y., Martin, L. R., Peleg, O., Ben‐Ezra, M., & Mijiritsky, E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073804 · Cited by 82
COVID-19 Vaccination in Developing Nations: Challenges and Opportunities for Innovation
Sheikh, A. B., Pal, S., Javed, N., & Shekhar, R. (2021) · Infectious Disease Reports · doi:10.3390/idr13020041 · Cited by 76
Generation and Characterization of Recombinant SARS-CoV-2 Expressing Reporter Genes
Chiem, K., Vasquez, D. M., Park, J., Platt, R. N., Anderson, T., Walter, M. R., Kobie, J. J., Ye, C., & Martínez‐Sobrido, L. (2021) · Journal of Virology · doi:10.1128/jvi.02209-20 · Cited by 68
Mittelman, M., Magen, O., Barda, N., Dagan, N., Oster, H. S., Leader, A., & Balicer, R. D. (2021) · Blood · doi:10.1182/blood.2021013768 · Cited by 78
Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery
van der Meel, R., Chen, S., Zaifman, J., Kulkarni, J. A., Zhang, X. R. S., Tam, Y. K., Bally, M. B., Schiffelers, R. M., Ciufolini, M. A., Cullis, P. R., et al. (2021) · Small · doi:10.1002/smll.202103025 · Cited by 75
The Transcriptional Response to Lung-Targeting Lipid Nanoparticles in Vivo
Radmand, A., Lokugamage, M. P., Kim, H., Dobrowolski, C. N., Zenhausern, R., Loughrey, D., Huayamares, S. G., Hatit, M. Z. C., Ni, H., Cid, A. D., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04479 · Cited by 79
Hou, Y., Lu, K., & Kuo, K. (2021) · Vaccines · doi:10.3390/vaccines9080885 · Cited by 74
“For BNT162b2, the full-length RNA with 2 mutation modified by proline can translate the locked-in perfusion transformation in order to augment the production of neutralizing antibody [27].”
BackgroundMyocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111106 · Cited by 76
“It was demonstrated that, in clinical trials, the efficacies of mRNA vaccines were over 90% [20,21].”
BackgroundSix months of COVID vaccines: what 1.7 billion doses have taught scientists
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-01505-x · Cited by 77
McMurry, R., Lenehan, P., Awasthi, S., Silvert, E., Puranik, A., Pawlowski, C., Venkatakrishnan, A. J., Anand, P., Agarwal, V., O’Horo, J. C., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.006 · Cited by 67
Schepens, B., van Schie, L., Nerinckx, W., Roose, K., Breedam, W. V., Fijałkowska, D., Devos, S., Weyts, W., Cae, S. D., Vanmarcke, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi7826 · Cited by 72
Castaldo, M., Waliszewska‐Prosół, M., Koutsokera, M., Robotti, M., Straburzyński, M., Apostolakopoulou, L., Capizzi, M., Çibuku, O., Ambat, F. D. F., Frattale, I., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01400-4 · Cited by 75
Wright, B. J., Tideman, S., Diaz, G. A., French, T., Parsons, G., & Robicsek, A. A. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00042-x · Cited by 69
Hsieh, S., Liu, W.-D., Huang, Y., Lin, Y., Hsieh, E.-F., Lian, W., Chen, C., Janssen, R. S., Shih, S., Huang, C., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100989 · Cited by 67
An overview on the treatments and prevention against COVID-19
Panahi, Y., Gorabi, A. M., Talaei, S., Beiraghdar, F., Akbarzadeh, A., Tarhriz, V., & Mellatyar, H. (2023) · Virology Journal · doi:10.1186/s12985-023-01973-9 · Cited by 82
“Pfizer/ BioNTech has announced efficacy of 95% [161].”
BackgroundSafety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
Boyarsky, B. J., Ou, M. T., Greenberg, R. S., Teles, A. T., Werbel, W. A., Avery, R. K., Massie, A. B., Segev, D. L., & Garonzik‐Wang, J. (2021) · Transplantation · doi:10.1097/tp.0000000000003654 · Cited by 72
Ou, M. T., Boyarsky, B. J., Chiang, T. P., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003824 · Cited by 66
Ouldali, N., Bagheri, H., Salvo, F., Antona, D., Pariente, A., Leblanc, C., Tebacher, M., Micallef, J., Lévy, C., Cohen, R., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100393 · Cited by 71
Engineering LNPs with polysarcosine lipids for mRNA delivery
Kang, D. D., Hou, X., Wang, L., Xue, Y., Li, H., Zhong, Y., Wang, S., Deng, B., McComb, D. W., & Dong, Y. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.03.017 · Cited by 124
“Lipid nanoparticles (LNPs) such as ALC-0315 and SM-102 LNPs have been applied to deliver mRNAs encoding viral antigens against the SARS-CoV-2 virus [1 – 3].”
MethodHueso, T., Godron, A.-S., Lanoy, É., Pacanowski, J., Levi, L. I., Gras, E., Surgers, L., Guemriche, A., Meynard, J., Pirenne, F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01511-6 · Cited by 70
“Indeed, initiation of the anti–SARS-CoV-2 vaccination [27], the availability and use of antispike mAbs in patients at risk of developing a severe form of COVID-19 [28], and the emergence of SARS-CoV-2 variants have changed the course of COVID-19 outbreak.”
BackgroundPost-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
Razok, A., Shams, A., Almeer, A., & Zahid, M. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102540 · Cited by 77
Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection
Norouzi, M., Norouzi, S., Ruggiero, A. D., Khan, M. S., Myers, S., Kavanagh, K., & Vemuri, R. (2021) · Microorganisms · doi:10.3390/microorganisms9061211 · Cited by 79
“Pfizer–BioNTech vaccine United States, Germany RNA 95% 12yrs and older 2 doses, 21 days apart(USA), 6 week(EU/UK) −80 ◦C Full use [103]”
BackgroundRovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F., Sammartino, J. C., Ferrari, A., Bergami, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26154-6 · Cited by 72
“Moreover, recently, highly effective vaccines have been introduced 43 [1-4].”
BackgroundResultImportance of COVID-19 vaccine efficacy in older age groups
Sadarangani, M., Raya, B. A., Conway, J. M., Iyaniwura, S. A., Falcão, R. C., Colijn, C., Coombs, D., & Gantt, S. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.020 · Cited by 70
Romero‐Olmedo, A. J., Schulz, A. R., Hochstätter, S., Gupta, D. D., Virta, I., Hirseland, H., Staudenraus, D., Camara, B., Münch, C., Hefter, V., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01046-z · Cited by 71
Cihan, P. (2021) · Applied Soft Computing · doi:10.1016/j.asoc.2021.107708 · Cited by 71
“Pfizer–BioNTech [8] 95% mRNA −70 C 2 Moderna [9] 94% mRNA −20 C 2 SputnikV [10] 91% Viral vector <=−18 C 2 AstraZeneca [9] 70% Viral vector 2–8 C 2 Convidecia [11] 66% Viral vector 2–8 C 1 Janssen [12] 76.”
Young, R. E., Nelson, K. M., Hofbauer, S. I., Vijayakumar, T., Alameh, M., Weissman, D., Papachristou, C., Gleghorn, J. P., & Riley, R. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.014 · Cited by 88
Kim, S., Jeon, J. H., Kim, M., Lee, Y., Hwang, Y.-H., Park, M., Li, C. H., Lee, T., Lee, J.-A., Kim, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51411-9 · Cited by 109
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 67
Hwang, J., Park, S. H., Lee, S. W., Lee, S. B., Lee, M. H., Jeong, G. H., Kim, M. S., Kim, J. Y., Koyanagi, A., Jacob, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab592 · Cited by 86
Callegaro, A., Borleri, D., Farina, C., Napolitano, G., Valenti, D., Rizzi, M., & Maggiolo, F. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26982 · Cited by 64
A New Vaccine to Battle Covid-19
Haynes, B. F. (2020) · New England Journal of Medicine · doi:10.1056/nejme2035557 · Cited by 71
SARS-CoV-2 vaccines for cancer patients: a call to action
Corti, C., Crimini, E., Tarantino, P., Pravettoni, G., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.046 · Cited by 71
Cardoso, R. V., Pereira, P. R., Freitas, C. S., & Paschoalin, V. M. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122808 · Cited by 76
Edahiro, R., Shirai, Y., Takeshima, Y., Sakakibara, S., Yamaguchi, Y., Murakami, T., Morita, T., Kato, Y., Liu, Y., Motooka, D., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01375-1 · Cited by 74
Geng, J., Xia, X., Teng, L., Wang, L., Chen, L., Guo, X., Belingon, B., Li, J., Feng, X., Li, X., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.032 · Cited by 71
Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination
Kadire, S. R., Wachter, R. M., & Lurie, N. (2021) · New England Journal of Medicine · doi:10.1056/nejmclde2101987 · Cited by 68
King, H. A. D., Joyce, M. G., Lakhal-Naouar, I., Ahmed, A., Cincotta, C. M., Subra, C., Peachman, K. K., Hack, H. R., Chen, R. E., Thomas, P. V., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106433118 · Cited by 67
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 83
Trimpert, J., Dietert, K., Firsching, T. C., Ebert, N., Thao, T. T. N., Vladimirova, D., Kaufer, S., Labroussaa, F., Abdelgawad, A., Conradie, A. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109493 · Cited by 68
Wastewater Surveillance during Mass COVID-19 Vaccination on a College Campus
Bivins, A., & Bibby, K. (2021) · Environmental Science and Technology Letters · doi:10.1021/acs.estlett.1c00519 · Cited by 82
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
van Leeuwen, L. P. M., GeurtsvanKessel, C. H., Ellerbroek, P. M., de Bree, G. J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F. L., Gorp, E. C. M. V., de Wilt, F., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.002 · Cited by 71
Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021) · mBio · doi:10.1128/mbio.01386-21 · Cited by 68
Alvim, R. G. F., Lima, T. M., Rodrigues, D. A. S., Marsili, F. F., Bozza, V. B. T., Higa, L. M., Monteiro, F. L. L., de Abreu, D. P. B., Leitão, I. C., Carvalho, R. S., et al. (2022) · Biochemical Engineering Journal · doi:10.1016/j.bej.2022.108537 · Cited by 68
Finkelstein, M. T., Mermelstein, A. G., Miller, E. P., Seth, P. C., Stancofski, E.-S. D., & Fera, D. (2021) · Viruses · doi:10.3390/v13010134 · Cited by 66
Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application
Mashima, R., & Takada, S. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100341 · Cited by 78
Plant extracellular vesicles: Trojan horses of cross‐kingdom warfare
He, B., Hamby, R., & Jin, H. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00040 · Cited by 69
Resta, C. D., Ferrari, D., Viganò, M., Moro, M., Sabetta, E., Minerva, M., Ambrosio, A. G., Locatelli, M., & Tomaiuolo, R. (2021) · Vaccines · doi:10.3390/vaccines9050522 · Cited by 70
“Finally, allergic reactions were limited in both males and females [52].”
BackgroundMilligan, J. C., Zeisner, T. U., Papageorgiou, G., Joshi, D., Soudy, C., Ulferts, R., Wu, M., Lim, C. T., Tan, K. W., Weissmann, F., et al. (2021) · Biochemical Journal · doi:10.1042/bcj20210197 · Cited by 68
Cavazza, A., Molina-Estévez, F. J., Reyes, Á. P., Ronco-Díaz, V., Naseem, A., Malenšek, Š., Pečan, P., Santini, A., Heredia, P., Aguilar-González, A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102457 · Cited by 80
Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development
Vallet, T., & Vignuzzi, M. (2025) · Viruses · doi:10.3390/v17040566 · Cited by 89
“These vaccines demonstrated remarkable efficacy in preventing severe illness and reducing virus transmission, with clinical trials showing efficacy rates exceeding 90% [22,23].”
Lipid nanoparticles for mRNA delivery in brain via systemic administration
Cao, D., Hou, X., Wang, C., Wang, S., Liu, Z., Tian, M., Guo, K., Li, H., Kang, D. D., Zhong, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw0730 · Cited by 91
Connolly, C. M., Ruddy, J. A., Boyarsky, B. J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220231 · Cited by 67
Wan, E. Y. F., Chui, C. S. L., Wang, Y., Ng, V. W. S., Yan, V. K. C., Lai, F. T. T., Li, X., Wong, C. K. H., Chan, E. W., Wong, C. S. M., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100393 · Cited by 73
Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
Misset, B., Piagnerelli, M., Hoste, E. A. J., Dardenne, N., Grimaldi, D., Michaux, I., Waele, E. D., Dumoulin, A., Jorens, P. G., van der Hauwaert, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2209502 · Cited by 74
Maringer, Y., Nelde, A., Schroeder, S. M., Schuhmacher, J., Hörber, S., Peter, A., Karbach, J., Jäger, E., & Walz, J. S. (2022) · Science Immunology · doi:10.1126/sciimmunol.add3899 · Cited by 72
Chan, A., Haley, R. M., Najar, M. A., Gonzalez-Martinez, D., Bugaj, L. J., Burslem, G. M., Mitchell, M. J., & Tsourkas, A. (2024) · Nature Communications · doi:10.1038/s41467-024-50235-x · Cited by 81
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 71
“Serum neutralization activity is a common predictor of protection against SARS‐CoV‐2 following natural infection or vaccination.(12,13) Due to variations observed in the spike genome, effective protection from SARS‐CoV‐2 infection requires a sufficient breadth of neutralizing antibodies rather than potency alone.”
BackgroundInfluentialShem‐Tov, N., Yerushalmi, R., Danylesko, I., Litachevsky, V., Levy, I., Olmer, L., Lusitg, Y., Avigdor, A., Nagler, A., Shimoni, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17918 · Cited by 65
“The Pfizer and Moderna clinical trials excluded immunocompromised patients.(2,3) The Israeli Ministry of Health research paper”
BackgroundCai, X., Drummond, C. J., Zhai, J., & Tran, N. L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404234 · Cited by 77
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.